Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FUMANBA-1 phase I/II study of CT103A in relapsed/refractory multiple myeloma
ChiCTR2000033946Phase 2Recruiting
- Sponsor
- Tongji Hospital, Huazhong University of Science and Technology
- Start
- Sep 2019
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of equecabtagene autoleucel in multiple myeloma (MM), sponsored by Tongji Hospital, Huazhong University of Science and Technology. Primary endpoints: Serum calcium and albumin-corrected calcium, Beta-2 microglobulin and 5 more. Started Sep 2019; status: recruiting.
02
Drugs
equecabtagene autoleucel
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ChiCTR2000033946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000033946.